Glioblastoma

An artificial intelligence algorithm that uses computational analysis to identify possible therapeutic targets for glioblastoma multiforme and other types of cancer could have broad treatment implications, according to its developers.

When administering chemotherapy to a patient with recurrent glioblastoma, physicians must overcome the blood-brain barrier, an immunologic feature of the central nervous system.

The addition of an autologous tumor lysate-loaded dendritic vaccine to standard care extended OS among certain patients with glioblastoma, according to results of a prospective phase 3 trial published in JAMA Oncology.

The FDA granted orphan drug designation to WP1122 for the treatment of glioblastoma multiforme, according to a press release from the agent’s manufacturer.

Ashish Shah, MD, has been named director of clinical trials and translational research at Sylvester Comprehensive Cancer Center’s Brain Tumor Initiative at University of Miami Miller School of Medicine.

Glioblastoma, the most common primary brain cancer, is known to be highly aggressive and deadly.

The FDA granted fast track designation to several oncology and hematology therapies.

Perhaps no one has been better prepared to become a leader in the field of cancer cellular immunotherapy than Marcela V. Maus, MD, PhD.

In this edition, Break Through Cancer awards $50M to fund a ‘radical collaboration’ in cancer research; the FDA grants a breakthrough device designation for an MS plasma test; App-based mental exercises may improve cognitive impairment; and more.

The FDA granted fast track and orphan drug designations to Alpheus Medical’s CV-01 delivery of sonodynamic therapy for treatment of recurrent glioblastoma.